Sanara MedTech Files Proxy Statement

TL;DR

Sanara MedTech filed its proxy statement, shareholders vote soon.

AI Summary

Sanara MedTech Inc. filed a Definitive Additional Materials proxy statement on May 15, 2024. This filing relates to the company's proxy statement for its annual meeting. The company, formerly known as Wound Management Technologies, Inc., is based in Fort Worth, Texas, and operates in the orthopedic, prosthetic & surgical appliances & supplies sector.

Why It Matters

This filing is a standard procedural document for public companies, informing shareholders about upcoming meetings and voting matters, which is crucial for corporate governance.

Risk Assessment

Risk Level: low — This is a routine SEC filing for a proxy statement, not indicating any immediate financial or operational risk.

Key Players & Entities

• Sanara MedTech Inc. (company) — Registrant
• Wound Management Technologies, Inc. (company) — Former company name
• 0001493152-24-019943 (filing_id) — Accession Number
• May 15, 2024 (date) — Filing Date

FAQ

Filing Documents

• formdefa14a.htm (DEFA14A) — 26KB
• formdefa14a_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-019943.txt ( ) — 32KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 SANARA MEDTECH INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. 1200 Summit Ave Suite 414 Fort Worth, Texas 76102 (817) 529-2300 SUPPLEMENT TO THE PROXY STATEMENT FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 12, 2024 Unless the context otherwise requires, references in this proxy statement supplement to “Sanara MedTech,” “Sanara,” the “Company,” “we,” “us,” or “our,” refer to Sanara MedTech Inc., a Texas corporation, and its consolidated subsidiaries as a whole . The following information supplements and amends the Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) that was filed by the Company with the Securities and Exchange Commission (the “SEC”) on April 15, 2024 and furnished to the Company’s shareholders in connection with the solicitation of proxies by the Company’s Board of Directors (the “Board”) for the Company’s 2024 annual meeting of shareholders (the “Annual Meeting”) and any postponement(s) or adjournment(s) thereof. This supplement to the Proxy Statement (this “Supplement”) is being filed with the SEC and being made available to shareholders on or about May 15, 2024. All capitalized terms not otherwise defined herein shall have their respective meanings as set forth in the Proxy Statement. In connection with the Annual Meeting, the Board previously (i) approved, subject to approval by shareholders of the Amended and Restated Certificate of Formation at the Annual Meeting and the filing of it with the Secretary of State of the State of Texas, an increase in the number of directors serving on the Board from eight (8) to nine (9) directors, with such increase to be effective as of the date the Amended and Restated Certificate of Formation is filed with and approved by the Secretary of State of the State of Texas, thereby resulting in a newly created directorship (the “Board Increase”) and (ii) nominated Zachary B. Fleming to stand for election as a director at the Annual Meeting to fill the newly created vacancy resulting from the Board Increase. As previously disclosed, on May 10, 2024, Mr. Fleming delivered notice to the Board that he was resigning from his position as Chief Executive Officer of the Company, effective immediately. As a result of Mr. Fleming’s resignation, the Board determined (i) to not effectuate the Board Increase and (ii) that the proposal to elect one director to fill a vacancy to be created from an increase in the size of the Board (“Proposal 3”) will not be presented at the Annual Meeting. The information in this Supplement is in addition to the information provided by the Proxy Statement, and except for the changes herein, this Supplement does not modify any other information set forth in the Proxy Statement. THE PROXY STATEMENT CONTAINS IMPORTANT ADDITIONAL INFORMATION, AND THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT . ADDITIONAL INFORMATION AND WHERE TO FIND IT In connection with the Annual Meeting, we previously filed our Proxy Statement with the SEC and made available our Proxy Statement, proxy card and documents incorporated by reference to our shareholders on April 15, 2024. Before making any voting decision, you are urged to read the Proxy Statement, including the documents incorporated by reference, and all related proxy materials carefully. Copies of this Supplement, the Proxy Statement, the Company’s official notice of Annual Meeting of Shareholders and the Company’s 2023 Annual Report, the documents incorporated by reference and all other proxy materials are available at http://onlineproxyvote.com/SMTI/2024 . We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith, file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an internet website at www.sec.gov that contains periodic and current reports, proxy and information statements and other information regarding registrants that are filed electronically with the SEC.

View Full Filing

View this DEFA14A filing on SEC EDGAR